Swiss Oncology in Motion Module Urothelial Carcinoma CME continuing education Education Oncology Partner Content RX Urology View Post
View Post This content is machine translated Online training Swiss Oncology in Motion Module Prostate Cancer Treatment options for prostate cancer have evolved rapidly over the past two years, with advances across the spectrum of disease stages. Prof. em. Dr. med Richard Herrmann speaks in the Prostate Cancer module of Swiss Oncology in Motion with Dr. med Tobias Gross (Inselspital Bern), Dr. med Marie-Laure Amram (Hirslanden) and Prof. Dr. med Richard Cathomas (Chur). CME-Test
View Post This content is machine translated Swiss Oncology in Motion SOiM Urothelial carcinoma – Update Oncology is constantly changing, with additional diagnostic procedures, new surgical methods and innovative therapeutic concepts being developed. For this reason, the treatment guidelines are also continuously revised. Therefore, this module of Swiss Oncology in Motion is dedicated to urothelial carcinoma. Prof. Dr. med. Richard Cathomas gives an overview of the most important information on urothelial carcinoma and the available treatment options and corresponding study data. CME-Test
View Post This content is machine translated Swiss Oncology in Motion Special “GENETIC INSTABILITY” In the special “GENETIC INSTABILITY” of Swiss Oncology in Motion, Prof. Dr. med. Viola Heinzelmann-Schwarz (University Hospital Basel), Prof. Dr. med. Jens Huober (Canton Hospital St. Gallen), PD Dr. med. Aurelius Omlin (OnkoZentrum Zürich), Prof. Dr. med. Dr. phil. Andreas Wicki (University Hospital Zurich) and Prof. Dr. med. Wolfram Jochum (Cantonal Hospital St. Gallen) discussed the role of genetic instability in various tumor types, in particular ovarian and endometrial carcinomas, breast carcionoma, GI tumors, and prostate, urothelial, and renal cell carcinomas, and how it influences treatment options. The discussion will be led by Prof. em. Richard Herrmann, MD, Basel, moderated. CME-Test
View Post This content is machine translated Acute myeloid leukemia (AML) “A new standard of care for elderly and fragile patients” A BCL-2 inhibitor is convincing in new studies in the first-line treatment of AML patients who are not suitable for intensive chemotherapy [1]. Hematologists Dr. Georgios Georgiou and Prof. Photis Beris assess the impact of these new data on the existing therapeutic landscape.
View Post This content is machine translated Editorial Swiss Oncology in Motion: Video-based online training courses Educational films in various modules for medical oncologists, hematologists and oncology specialists. Oncology is on the move – research is advancing rapidly and new insights into biology and therapy are constantly being gained. On the Swiss Oncology in Motion platform, relevant oncology topics are presented in modules with three expert presentations each as video training including CME questions.
View Post This content is machine translated Online training Swiss Oncology in Motion Chronic Lymphocytic Leukemia Module The Chronic Lymphocytic Leukemia module of Swiss Oncology in Motion includes articles by Prof. em. Richard Herrmann, MD, moderated presentations by PD Jeroen S. Goede, MD, Head of Hematology (Head of the Center for Lymphomas and Leukemias), Michael Gregor, MD, Head of Hematology (Lucerne Cantonal Hospital) and Prof. Thorsten Zenz, MD, Head of the Center for Hematology and Oncology (University Hospital Zurich).
